Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

National Institute of Allergy and Infectious Diseases (NIAID)

Status and phase: Completed; Phase 2

Conditions: Sexually Transmitted Diseases; HIV Infections

Treatments: Biological: Quadrivalent HPV vaccine

Study type: Interventional

Funder types: NIH

Identifiers

NCT00604175

A5240

ACTG A5240

10393 (Registry Identifier)

Details and patient eligibility

About

Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer. HPV infection may be more severe and harder to treat in HIV-infected people. The purpose of this study was to determine whether the quadrivalent HPV vaccine is safe, tolerable, and effective in producing antibodies to HPV in HIV-infected women.

Full description

HPV is a DNA virus that affects both men and women. Approximately 90 types of HPV have been identified, 30 of which are sexually transmitted. The most common forms of HPV are types 6, 11, 16, and 18. The quadrivalent HPV vaccine that was tested in this study had been shown in previous studies to be effective in preventing infection with HPV 6, 11, 16, and 18 in healthy young women. According to a report by the Centers for Disease Control and Prevention (CDC), 80% of women will have acquired HPV by the age of 50. HIV infected women have been reported to have a higher prevalence and persistence of HPV infection, as well as an increased risk for abnormal Pap smears and cervical cancer. HPV types 16 and 18 cause the majority of cervical cancers worldwide, and types 6 and 11 are responsible for the majority of cases of genital warts. Vaccinations for preventable infections are particularly important among HIV infected people because people with HIV have compromised immune systems; therefore, any infection is very serious and can potentially be fatal. However, standard vaccination series have not been very successful because a compromised immune system may not produce the desired immune response to a vaccine. The HPV vaccine is designed to protect against infection with HPV types 6, 11, 16, and 18 and has been approved by the FDA for use in women between the ages of 9 and 26. The purpose of this study was to determine whether the quadrivalent HPV vaccine is safe, tolerable, and effective in producing antibodies to HPV in HIV infected females.

The study consisted of single arm evaluations of HPV vaccine immunogenicity and safety in 3 groups based on the study screening CD4 cell count as follows:

• Stratum A: CD4 cell count >350 cells/mm^3
• Stratum B: CD4 cell count >200 to <=350 cells/mm^3
• Stratum C: CD4 cell count <=200 cells/mm^3

In Version 1.0 of the protocol, the target accrual was n=67 participants with screening HIV viral load <=10,000 copies/mL and n=67 participants with HIV viral load >10,000 copies/mL within each CD4 stratum, yielding n=134 in each CD4 stratum. In light of subsequent findings from completed HPV vaccine studies, the sample size was changed to n=94 participants per CD4 stratum in Version 2.0 of the protocol, and stratification by screening HIV viral load was removed. All Stratum A and Stratum B participants were enrolled under protocol Version 1.0.

The study duration was 72 weeks. All participants received HPV vaccine administered by intramuscular injection at baseline, and at Weeks 8 and 24. Following each injection, participants remained at the clinic for 30 minutes of observation for adverse events. A telephone follow-up or a home visit by study staff was performed within 2 days following each injection.

Participants returned to the clinic for visits at Weeks 4, 8, 12, 24, 28, 52, and 72. Most study visits included a physical exam, medication review, blood and urine collection, and answering questions about signs and symptoms since previous visit. Some visits included measurement of HIV viral load and CD4 cell count; collection of endocervical wick, cervical cytobrush and anal swab; and an oral exam. A subset of participants were asked to provide additional blood samples and oral cytobrush specimens.

Enrollment: 319 patients

Sex: Female

Ages: 13 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV infection

• CD4 count obtained within 45 days prior to study entry

• Karnofsky performance score >=70 on at least one occasion within 45 days prior to study entry

• The following labs within 45 days prior to study entry:

  • hemoglobin >8.0 g/dL
  • direct bilirubin <2.5 x upper limit of normal (ULN)
  • alanine aminotransferase, ALT (SGPT) <3 xULN
  • aspartate aminotransferase, AST (SGOT) <3 xULN
  • platelet count >=100,000 /mm^3

• Willing to use acceptable forms of contraception for the duration of the study

• Written informed consent from participant or from parent or guardian, if applicable

• If on HAART, then the same regimen for at least 12 weeks prior to study entry with no change within 30 days prior to study entry. (This criterion was removed in Version 2.0 of the protocol.)

• HIV viral load obtained within 45 days prior to study entry (This criterion was removed in Version 2.0 of the protocol.)

Exclusion criteria

• Abnormal Pap test with confirmed biopsy results of cervical intraepithelial neoplasia (CIN) II or III or cervical cancer within 180 days prior to study entry
• Vulval intraepithelial neoplasia (VIN) II or III or cancer confirmed by biopsy results within 180 days prior to study entry
• Physician-diagnosed genital warts within 180 days prior to study entry
• Previous cervical dysplasia treatment, including loop electrosurgical excision procedure (LEEP), cervical cryotherapy, cone biopsy, and cervical laser vaporization within 180 days prior to study entry
• Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin (IVIG) within 45 days prior to study entry. Participants who had received standard of care (e.g., hepatitis B, influenza, and tetanus) vaccines were not excluded.
• Known allergy or hypersensitivity to yeast or any components of the vaccine or its formulation
• Current drug or alcohol use or dependence or any other condition that may interfere with study participation
• Serious illness requiring systemic treatment and/or hospitalization within 45 days prior to study entry
• Total hysterectomy. Participants who had undergone partial hysterectomy and had a cervix were not excluded.
• Hemophilia
• Currently on anticoagulation therapy other than acetylsalicylic acid
• Prior vaccination with an HPV vaccine
• Pregnant or breastfeeding

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

319 participants in 3 patient groups

Stratum A

Experimental group

Description:

Participants with screening CD4 count \>350 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.

Treatment:

Biological: Quadrivalent HPV vaccine

Stratum B

Experimental group

Description:

Participants with screening CD4 count \>200 to \<=350 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.

Treatment:

Biological: Quadrivalent HPV vaccine

Stratum C

Experimental group

Description:

Participants with screening CD4 count \<=200 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.

Treatment:

Biological: Quadrivalent HPV vaccine